ArticleUnited European gastroenterology journal2015
Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.
Article in United European gastroenterology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2020Pooled it
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.The American journal of gastroenterology · 2019Pooled it
- Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.Inflammatory bowel diseases · 2017Pooled it
- Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.Digestive diseases (Basel, Switzerland) · 2024Trial
- Treat-to-Target in Ulcerative Colitis: How Soon Is Now?Journal of clinical medicine · 2026Article
- Irritable Bowel Syndrome Prevalence in Patients with Inflammatory Bowel Disease in Remission: Single-Center Experience.Clinical and experimental gastroenterology · 2026Article
- Comparative Value of CRP and FCP for Endoscopic and Histologic Remissions in Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2024Article
- Disease clearance in ulcerative colitis: A new therapeutic target for the future.World journal of gastroenterology · 2024Article
- Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.BMC gastroenterology · 2022Article
- Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.BMJ open gastroenterology · 2022Article
- Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse.International journal of colorectal disease · 2021Article
- Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis.Scientific reports · 2021Article
- Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?Paediatric drugs · 2020Review
- Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis.Journal of clinical medicine · 2020Review
- Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?World journal of gastroenterology · 2019Review
- Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type.Journal of clinical biochemistry and nutrition · 2019Article
- Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease.Frontiers in pediatrics · 2017Article
- Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.Gastroenterology research and practice · 2017Article
- Optimizing biologic treatment in IBD: objective measures, but when, how and how often?BMC gastroenterology · 2015Review
- Disease monitoring in inflammatory bowel disease.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTargeted therapy, using biomarkers to assess disease activity in ulcerative colitis (UC), has been proposed.
objectiveThe objective of this study was to evaluate whether pharmacological intervention guided by fecal calprotectin (FC) prolongs remission in patients with UC.
methodsA total of 91 adults with UC in remission were randomized to an intervention group or a control group. Analysis of FC was performed monthly, during 18 months. A FC value of 300 µg/g was set as the cut-off for intervention, which was a dose escalation of the oral 5-aminosalicylate (5-ASA) agent. The primary study end-point was the number of patients to have relapsed by month 18.
resultsThere were relapses in 18 (35.3%) and 20 (50.0%) patients in the intervention and the control groups, respectively (p = 0.23); and 28 (54.9%) patients in the intervention group and 28 (70.0%) patients in the control group had a FC > 300 µg/g, of which 8 (28.6%) and 16 (57.1%) relapsed, respectively (p < 0.05).
conclusionActive intervention significantly reduced relapse rates, although no significant difference was reached between the groups overall. Thus, FC-levels might be used to identify patients with UC at risk for a flare, and a dose escalation of their 5-ASA agent is a therapeutic option for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.